The Zephyr Platform combines multi-modal AI, enterprise-scale real-world data, and deeply profiled oncology cohorts—delivered on secure, compliant infrastructure built for speed and scale. Our solutions integrate seamlessly into partner workflows to de-risk development, optimize patient selection, and accelerate clinical translation—driving solutions from discovery to deployment.
Predict response to small molecules or immune checkpoint inhibitors using clinically available data. Validated in real-world cohorts, outperforming conventional biomarkers, and adaptable as AI-CDx for partner drugs.
Fine-tuned companion diagnostics co-developed with biopharma and diagnostics partners. Built on AIM-Bx and adapted to partner assays and assets with preclinical or clinical data.
Reconstructs mRNA expression from DNA-based LDTs and minimal clinical data with high concordance to RNAseq. Enhances interpretability and feeds downstream models with biologically rich expression-level inputs.
Nexus transforms EHR, claims, genomics, and pathology data into actionable insights for discovery, validation, and market strategy.
Extract intelligence from 90M+ patients across oncology (1M+ with NGS) and chronic disease.
Define fit-for-purpose populations and credible comparator arms for trials and HEOR.
Train, test, and refine predictive models on linked longitudinal data.
Predict outcomes and costs to inform pricing, access, and value-based care strategies.
Aster Avatar: matched clinical, exome, transcriptome, and digital pathology data with longitudinal updates–ideal for translational research and biomarker discovery.
Generate new molecular data to power discovery, validation, and regulatory programs.
Our investment in these systems means models move seamlessly from concept to production.
Zephyr can launch proof-of-concept pilots in weeks and scale them to clinical and commercial applications without re-engineering.
Zephyr’s platform bridges experimental and clinical domains, extracting hidden signals from large multi-modal datasets to deliver actionable insights that drive discovery, validation, and co-development. Partners benefit from models enriched with deep biological context—shaped by learnings across vast drug, tumor, and patient landscapes—yet adaptable and fine-tunable to their unique assets.
